Emory University sold its royalties on the drug to Royalty Pharma and Gilead Sciences in July 2005 for $525 million.
ˈɛmɚɹi jˌuːnɪvˈɜːsᵻɾi sˈoʊld ɪts ɹˈɔɪəlɾiz ɔnðə dɹˈʌɡ tə ɹˈɔɪəlɾi fˈɑːɹmə ænd ɡˈɪliˌæd sˈaɪənsᵻz ɪn dʒuːlˈaɪ tˈuː θˈaʊzənd fˈaɪv fɔːɹ dˈɑːlɚ fˈaɪvhˈʌndɹɪd twˈɛnti fˈaɪv mˈɪliən.